BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 15690057)

  • 21. P21 and Bax expression in cutaneous malignant melanomas: correlation with histologic prognostic parameters.
    Poyraz A; Akyürek N; Gönül II; Erdem O
    J Exp Clin Cancer Res; 2004 Dec; 23(4):625-31. PubMed ID: 15743033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.
    Alonso SR; Tracey L; Ortiz P; Pérez-Gómez B; Palacios J; Pollán M; Linares J; Serrano S; Sáez-Castillo AI; Sánchez L; Pajares R; Sánchez-Aguilera A; Artiga MJ; Piris MA; Rodríguez-Peralto JL
    Cancer Res; 2007 Apr; 67(7):3450-60. PubMed ID: 17409456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 plays a central role in UVA and UVB induced cell damage and apoptosis in melanoma cells.
    Zhang H
    Cancer Lett; 2006 Dec; 244(2):229-38. PubMed ID: 16504377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of allelic losses in primary melanoma.
    Healy E; Belgaid C; Takata M; Harrison D; Zhu NW; Burd DA; Rigby HS; Matthews JN; Rees JL
    Oncogene; 1998 Apr; 16(17):2213-8. PubMed ID: 9619830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of APAF-1 expression in human cutaneous melanoma progression.
    Baldi A; Santini D; Russo P; Catricalà C; Amantea A; Picardo M; Tatangelo F; Botti G; Dragonetti E; Murace R; Tonini G; Natali PG; Baldi F; Paggi MG
    Exp Dermatol; 2004 Feb; 13(2):93-7. PubMed ID: 15009102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the ets-1 proto-oncogene in melanocytic lesions.
    Keehn CA; Smoller BR; Morgan MB
    Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.
    Diallo JS; Aldejmah A; Mouhim AF; Péant B; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
    Clin Cancer Res; 2007 Dec; 13(23):7044-52. PubMed ID: 18056181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of ING4 in human melanoma cell migration, invasion and patient survival.
    Li J; Martinka M; Li G
    Carcinogenesis; 2008 Jul; 29(7):1373-9. PubMed ID: 18375955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas.
    Richmond-Sinclair NM; Lee E; Cummings MC; Williamson R; Muller K; Green AC; Hayward NK; Whiteman DC
    Melanoma Res; 2008 Oct; 18(5):336-45. PubMed ID: 18781132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma.
    Ding Y; Prieto VG; Zhang PS; Rosenthal S; Smith KJ; Skelton HG; Diwan AH
    Cancer; 2006 Mar; 106(5):1123-9. PubMed ID: 16456815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of thyrotropin-releasing hormone by human melanoma and nevi.
    Ellerhorst JA; Naderi AA; Johnson MK; Pelletier P; Prieto VG; Diwan AH; Johnson MM; Gunn DC; Yekell S; Grimm EA
    Clin Cancer Res; 2004 Aug; 10(16):5531-6. PubMed ID: 15328193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
    Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
    Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER3 is a determinant for poor prognosis in melanoma.
    Reschke M; Mihic-Probst D; van der Horst EH; Knyazev P; Wild PJ; Hutterer M; Meyer S; Dummer R; Moch H; Ullrich A
    Clin Cancer Res; 2008 Aug; 14(16):5188-97. PubMed ID: 18698037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
    Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
    Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance.
    Chen N; Gong J; Chen X; Meng W; Huang Y; Zhao F; Wang L; Zhou Q
    Hum Pathol; 2009 Jul; 40(7):950-6. PubMed ID: 19269012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
    Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
    Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway.
    Concannon CG; Koehler BF; Reimertz C; Murphy BM; Bonner C; Thurow N; Ward MW; Villunger A; Strasser A; Kögel D; Prehn JH
    Oncogene; 2007 Mar; 26(12):1681-92. PubMed ID: 16983338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NBS1 expression as a prognostic marker in uveal melanoma.
    Ehlers JP; Harbour JW
    Clin Cancer Res; 2005 Mar; 11(5):1849-53. PubMed ID: 15756009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.